淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展

doi:10.12114/j.issn.1007-9572.2021.00.600

摘要/Abstract

摘要： 静脉血栓（VTE）是恶性肿瘤的常见并发症，亦是导致肿瘤患者死亡的第二位非肿瘤致死因素。淋巴瘤是VTE发病率较高的肿瘤之一，然而，目前针对淋巴瘤相关VTE风险的危险因素以及防治方法尚未达到一致共识。因此，本文将结合最新指南及文献总结，将淋巴瘤相关VTE的影响因素及预测模型作一综述，分别介绍与淋巴瘤疾病本身、临床检验指标以及抗肿瘤治疗相关的VTE危险因素。同时，将4种VTE预测模型（即：Khorana评分、Ottawa评分、Michigan评分以及ThroLy评分）对淋巴瘤VTE风险的预测价值进行分析，为淋巴瘤相关VTE的防治提供新的指导。

关键词: 淋巴瘤, 静脉血栓, 影响因素, 预后模型, 综述

Abstract: Venous thromboembolism（VTE）is a common complication，and the second leading non-cancer cause of death in cancer patients. Lymphoma is a type of cancer with a high incidence of VTE. However，there is no consensus on the risk factors and prevention methods for lymphoma-associated VTE. To provide the latest guidance on the prevention and treatment of lymphoma-associated VTE，in reviewing the recent guidelines and literature，we overviewed the influencing factors of lymphoma-associated VTE，including types and treatment of lymphoma，clinical laboratory indicators and anti-tumor therapies. Besides that，we also summarized and analyzed the recently developed risk prediction models for lymphoma-associated VTE，including the Khorana Risk Score，Ottawa Score，Michigan Risk Score and ThroLy Lymphoma Score.

Key words: Lymphoma, Venous thromboembolism, Influence factors, Prognostic model, Review

杨婧诗,邹立群. 淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展[J]. 中国全科医学, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.
YANG Jingshi,ZOU Liqun. New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism　[J]. Chinese General Practice, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.

参考文献

［1］TIMP J F，BRAEKKAN S K，VERSTEEG H H，et al. Epidemiology of cancer-associated venous thrombosis［J］. Blood，2013，122（10）：1712-1723. DOI：10.1182/blood-2013-04-460121.
［2］KHORANA A A，KUDERER N M，CULAKOVA E，et al. Development and validation of a predictive model for chemotherapy-associated thrombosis［J］. Blood，2008，111（10）：4902-4907. DOI：10.1182/blood-2007-10-116327.
［3］ANTIC D，MILIC N，NIKOLOVSKI S，et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients［J］. Am J Hematol，2016，91（10）：1014-1019. DOI：10.1002/ajh.24466.
［4］YOKOYAMA K. Thrombosis in lymphoma patients and in myeloma patients［J］. Keio J Med，2015，64（3）：37-43. DOI：10.2302/kjm.2014-0017-RE.
［5］KEKRE N，CONNORS J M. Venous thromboembolism incidence in hematologic malignancies［J］. Blood Rev，2019，33：24-32. DOI：10.1016/j.blre.2018.06.002.
［6］GOLDSCHMIDT N，LINETSKY E，SHALOM E，et al. High incidence of thromboembolism in patients with central nervous system lymphoma［J］. Cancer，2003，98（6）：1239-1242. DOI：10.1002/cncr.11623.
［7］BYUN J M，HONG J，YOON S S，et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy［J］. Thromb Res，2019，183：131-135. DOI：10.1016/j.thromres.2019.10.002.
［8］ZHOU X，TEEGALA S，HUEN A，et al. Incidence and risk factors of venous thromboembolic events in lymphoma［J］. Am J Med，2010，123（10）：935-941. DOI：10.1016/j.amjmed.2010.05.021.
［9］FARGE D，BOUNAMEAUX H，BRENNER B，et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer［J］. Lancet Oncol，2016，17（10）：e452-466. DOI：10.1016/S1470-2045（16）30369-2.
［10］AY C，VORMITTAG R，DUNKLER D，et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer：results from the Vienna Cancer and Thrombosis Study［J］. J Clin Oncol，2009，27（25）：4124-4129. DOI：10.1200/JCO.2008.21.7752.
［11］LEKOVIC D，MILJIC P，MIHALJEVIC B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma［J］. Thromb Res，2010，126（6）：477-480. DOI：10.1016/j.thromres.2010.08.017.
［12］SAMUELSON BANNOW B T，KONKLE B A. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies：a review［J］. Thromb Res，2018，163：138-145. DOI：10.1016/j.thromres.2018.01.037.
［13］NEGAARD H F S，IVERSEN P O，?STENSTAD B，et al. Hypercoagulability in patients with haematological neoplasia：no apparent initiation by tissue factor［J］. Thromb Haemost，2008，99（6）：1040-1048. DOI：10.1160/TH07-09-0541.
［14］RUPA-MATYSEK J，GIL L，BARANSKA M，et al. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma［J］. Oncotarget，2018，9（30）：21190-21200. DOI：10.18632/oncotarget.25002.
［15］RUPA-MATYSEK J，GIL L，KROLL-BALCERZAK R，et al. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma［J］. Hematol Oncol，2017，35（4）：456-464. DOI：10.1002/hon.2321.
［16］RIEDL J，KAIDER A，REITTER E M，et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study（CATS）［J］. Thromb Haemost，2014，111（4）：670-678. DOI：10.1160/TH13-07-0603.
［17］YILDIZ A，ALBAYRAK M，PALA ?，et al. The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients：a 9-year single-center experience ［J］. J Oncol Pharm Pract，2020，26（2）：386-396. DOI：10.1177/1078155219851540.
［18］LI J S，TIAN X D，WANG M J，et al. A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis［J］. Onco Targets Ther，2018，11：9007-9011. DOI：10.2147/OTT.S183298.
［19］PARK H，KIM J W，YOUK J，et al. Serum free light chain difference and β2 microglobulin levels are risk factors for thromboembolic events in patients with AL amyloidosis［J］. Clin Lymphoma Myeloma Leuk，2018，18（6）：408-414. DOI：10.1016/j.clml.2018.03.005.
［20］RUPA-MATYSEK J，GIL L，KAZMIERCZAK M，et al. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies：validation of the Khorana Risk Score［J］. Med Oncol，2017，35（1）：5. DOI：10.1007/s12032-017-1065-4.
［21］JACCARD A，GACHARD N，MARIN B，et al. Efficacy of L-asparaginase with methotrexate and dexamethasone（AspaMetDex regimen）in patients with refractory or relapsing extranodal NK/T-cell lymphoma，a phase 2 study［J］. Blood，2011，117（6）：1834-1839. DOI：10.1182/blood-2010-09-307454.
［22］DE STEFANO V，ZA T，CIMINELLO A，et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences［J］. Thromb Haemost，2015，113（2）：247-261. DOI：10.1160/TH14-04-0372.
［23］LEE J H，LEE J，YHIM H Y，et al. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea［J］. J Thromb Haemost，2017，15（4）：655-661. DOI：10.1111/jth.13636.
［24］SANFILIPPO K M，WANG T F，GAGE B F，et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma［J］. Thromb Res，2016，143：86-90. DOI：10.1016/j.thromres.2016.05.008.
［25］ZANGARI M，SIEGEL E，BARLOGIE B，et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide：implications for therapy［J］. Blood，2002，100（4）：1168-1171. DOI：10.1182/blood-2002-01-0335.
［26］PAREDES N，XU L，BERRY L R，et al. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces［J］. Br J Haematol，2003，120（2）：315-324. DOI：10.1046/j.1365-2141.2003.03971.x.
［27］DAVID R J，BARAN A，LOH K P，et al. Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma［J］. Clin Lymphoma Myeloma Leuk，2018，18（12）：781-787. DOI：10.1016/j.clml.2018.08.014.
［28］ARORA M，GOWDA S，TUSCANO J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma［J］. Ther Adv Hematol，2016，7（4）：209-221. DOI：10.1177/2040620716652861.
［29］NOWAKOWSKI G S，LAPLANT B，MACON W R，et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma：a phase Ⅱstudy［J］. J Clin Oncol，2015，33（3）：251-257. DOI：10.1200/JCO.2014.55.5714.
［30］ALBERTSSON-LINDBLAD A，KOLSTAD A，LAURELL A，et al.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma［J］. Blood，2016，128（14）：1814-1820. DOI：10.1182/blood-2016-03-704023.
［31］NOWAKOWSKI G S，LAPLANT B，HABERMANN T M，et al. Lenalidomide can be safely combined with R-CHOP（R2CHOP）in the initial chemotherapy for aggressive B-cell lymphomas：phase I study［J］. Leukemia，2011，25（12）：1877-1881. DOI：10.1038/leu.2011.165.
［32］PAL R，MONAGHAN S A，HASSETT A C，et al. Immunomodulatory derivatives induce PU. 1 down-regulation，myeloid maturation arrest，and neutropenia［J］. Blood，2010，115（3）：605-614. DOI：10.1182/blood-2009-05-221077.
［33］YAMSHON S，CHRISTOS P J，DEMETRES M，et al. Venous thromboembolism in patients with B-cell non-hodgkin lymphoma treated with lenalidomide：a systematic review and meta-analysis［J］. Blood Adv，2018，2（12）：1429-1438. DOI：10.1182/bloodadvances.2018016683.
［34］KEY N S，KHORANA A A，KUDERER N M，et al. Venous thromboembolism prophylaxis and treatment in patients with cancer：ASCO clinical practice guideline update［J］. J Clin Oncol，2020，38（5）：496-520. DOI：10.1200/JCO.19.01461.
［35］SANTI RM，CECCARELLI M，BERNOCCO E，et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi（FIL）［J］. Thromb Haemost，2017，10.1160/TH16-11-0895. DOI：10.1160/TH16-11-0895.
［36］HOHAUS S，TISI M C，BARTOLOMEI F，et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization［J］. Blood Cancer J，2018，8（6）：54. DOI：10.1038/s41408-018-0096-1.
［37］LOUZADA M L，CARRIER M，LAZO-LANGNER A，et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism［J］. Circulation，2012，126（4）：448-454. DOI：10.1161/CIRCULATIONAHA.111.051920.
［38］DEN EXTER P L，KOOIMAN J，HUISMAN M V. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis［J］. J Thromb Haemost，2013，11（5）：998-1000. DOI：10.1111/jth.12192.
［39］ALATRI A，MAZZOLAI L，FONT C，et al. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry［J］. Thromb Haemost，2017，117（8）：1630-1636. DOI：10.1160/TH17-02-0116.
［40］CHOPRA V，KAATZ S，CONLON A，et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis［J］. J Thromb Haemost，2017，15（10）：1951-1962. DOI：10.1111/jth.13794.
［41］LUND J L，?STG?RD L S，PRANDONI P，et al. Incidence，determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark［J］. Thromb Res，2015，136（5）：917-923. DOI：10.1016/j.thromres.2015.09.001.
［42］JASTI N，STREIFF M B. Prevention and treatment of thrombosis associated with central venous catheters in cancer patients［J］. Expert Rev Hematol，2014，7（5）：599-616. DOI：10.1586/17474086.2014.954541.
［43］RUPA-MATYSEK J，BRZEZNIAKIEWICZ-JANUS K，GIL L，et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice ［J］. Cancer Med，2018，7（7）：2868-2875. DOI：10.1002/cam4.1540.
［44］KHORANA A A，FRANCIS C W，CULAKOVA E，et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy ［J］. J Thromb Haemost，2007，5（3）：632–634. DOI：10.1111/j.1538-7836.2007.02374.x.
［45］MAHAJAN A，BRUNSON A，WHITE R，et al. The epidemiology of cancer-associated venous thromboembolism：an update［J］. Semin Thromb Hemost，2019，45（4）：321-325. DOI：10.1055/s-0039-1688494.

[1]	秦凤银, 张绮珊, 赖锦佳, 黄奕敏, 韩郭茵, 孙兴兰, 王芬, 谭益冰. 广东省社区居民脑卒中高危筛查意向的现状及影响因素研究[J]. 中国全科医学, 2023, 26(34): 4283-4289.
[2]	郝爱华, 曾韦霖, 李观海, 夏英华, 陈亮. 基于全科医生视角的家庭医生团队签约现状调查研究[J]. 中国全科医学, 2023, 26(34): 4261-4268.
[3]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[4]	王越, 陈晴, 刘鲁蓉. 中国老年人抑郁检出率及影响因素的Meta分析[J]. 中国全科医学, 2023, 26(34): 4329-4335.
[5]	周俞余, 高川, 崔埔安, 王亚平, 何仲. 更年期综合征患者绝经激素治疗中医患共同决策质量的影响因素研究[J]. 中国全科医学, 2023, 26(33): 4181-4186.
[6]	王丽娜, 高鹏飞, 曹帆, 葛莹, 颜维, 何岱昆. 不同性别人群非酒精性脂肪性肝病患病现况及影响因素分析[J]. 中国全科医学, 2023, 26(33): 4143-4151.
[7]	李芊芊, 陈循睿, 张文颖, 袁海花, 张燕捷, 姜斌, 刘峰. 晚期肿瘤患者化疗期间对社区卫生服务需求的调查及影响因素研究[J]. 中国全科医学, 2023, 26(33): 4173-4180.
[8]	彰金, 丁治国, 祁烁, 李颖, 李伟强, 张媛媛, 周通. 血清甲状腺激素水平与心力衰竭患者住院期间预后的相关性研究[J]. 中国全科医学, 2023, 26(33): 4125-4129.
[9]	梁譞, 那飞扬, 秦梦瑶, 杨辉, 郭丽, 郭琪, 任蕾, 陈德, 刘东海, 张蓉芳. 儿童支气管哮喘合并阻塞性睡眠呼吸暂停低通气综合征的临床特征及影响因素研究[J]. 中国全科医学, 2023, 26(33): 4225-4230.
[10]	高德康, 危少华, 马孝明, 杜鹏, 邢春根, 曹春. 肝癌大范围肝切除术后骨骼肌减少的危险因素及其与术后并发症的相关性研究[J]. 中国全科医学, 2023, 26(32): 4031-4037.
[11]	张娟, 李海芬, 李小曼, 姚苗, 马惠珍, 马强. 糖尿病足溃疡复发风险预测模型的构建：基于Logistic回归和支持向量机及BP神经网络模型[J]. 中国全科医学, 2023, 26(32): 4013-4019.
[12]	高婧, 周尚成, 高三德, 邹冠炀, 陈颖尧. 基于欧洲五维健康量表的中医治未病门诊就诊患者健康相关生命质量及影响因素研究[J]. 中国全科医学, 2023, 26(32): 4043-4050.
[13]	马丽媛, 王增武, 樊静, 胡盛寿. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 26(32): 3975-3994.
[14]	王明欢, 李玉红, 俞敏, 王友刚, 俞巧稚, 杨方方, 袁德慧, 张柳. 妊娠晚期女性非稳态负荷对不良妊娠结局的影响研究[J]. 中国全科医学, 2023, 26(32): 4064-4069.
[15]	袁德慧, 李玉红, 熊敏, 俞敏, 马瑞亮, 杨方方, 俞巧稚, 王明欢. 妊娠女性不同时期非稳态负荷状况及其影响因素研究[J]. 中国全科医学, 2023, 26(32): 4057-4063.